Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant plus adjuvant Cemiplimab in high-risk resectable stage III/IV (M0) cutaneous squamous cell carcinoma
2024-515204-39-00Phase 2Authorised
- Sponsor
- Fondazione Melanoma Onlus
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Fondazione Melanoma Onlus. Primary endpoints: Major pathological response rate, Recurrence-free survival and 3 more. Planned start Nov 2024; status: authorised.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2024-515204-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515204-39-00.